An inexpensive anti-depressant curbed the number of COVID-19 patients ending up in hospital by 30 per cent, making it a potential breakthrough treatment for a virus that continues to spread widely, a Canadian-led clinical trial is reporting. If confirmed by more research, the drug, fluvoxamine, would be one of the most effective and convenient to treat the virus outside of pricey new “monoclonal antibodies.” They typically have to be administered in a hospital, as opposed to a pill taken orally at home. Fluvoxamine is given early in the course of the disease, potentially staving off more severe outcomes and their...